Pyrimethamine
Toxoplasmosis
National Institute of Allergy and Infectious Diseases (NIAID)Small moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Toxoplasmosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Valproic Acid University of Pittsburgh | Phase 4 | BB |
SPIRAMYCIN National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 | BB |
Sulfadiazine National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 | B |
Same molecule, other indications
Pyrimethamine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →